

Antipsychotic Drugs Market - Strategic Insights and Forecasts (2026-2031)

<https://marketpublishers.com/r/A11D12E57D11EN.html>

Date: February 2026

Pages: 142

Price: US\$ 3,950.00 (Single User License)

ID: A11D12E57D11EN

Abstracts

The global antipsychotic drugs market is forecast to grow at a CAGR of 6.5%, reaching USD 28.8 billion in 2031 from USD 21.0 billion in 2026.

The antipsychotic drugs market plays a central role in the treatment of severe mental disorders such as schizophrenia, bipolar disorder, and psychosis. Its strategic importance is reinforced by rising global awareness of mental health conditions and expanding access to psychiatric care. Macro drivers include demographic growth, urban stress factors, and improved diagnosis rates. Healthcare systems are prioritizing long term management of psychiatric illnesses, which supports sustained demand for antipsychotic therapies. The market also benefits from continuous pharmaceutical innovation and broader insurance coverage for mental health treatments.

Market Drivers

The primary growth driver is the increasing prevalence of psychiatric and neurological disorders worldwide. Aging populations contribute to higher incidence of cognitive and behavioral conditions requiring pharmacological intervention. Improved screening and early diagnosis strengthen prescription volumes. Expansion of healthcare infrastructure in developing regions supports wider access to treatment. Government initiatives aimed at reducing the burden of mental illness and improving community based care also encourage market expansion. The introduction of second generation and long acting injectable antipsychotics improves patient adherence and clinical outcomes, reinforcing demand. Growing acceptance of combination therapy further supports product utilization across hospital and outpatient settings.

Market Restraints

Adverse side effects associated with antipsychotic drugs remain a significant limitation. Weight gain, metabolic disorders, and neurological complications affect long term patient compliance. High treatment costs in certain regions restrict accessibility for low income populations. Social stigma related to mental illness reduces diagnosis and treatment uptake in several countries. Regulatory scrutiny on drug safety and post marketing surveillance increases development complexity and compliance costs for manufacturers. Patent expirations and price pressure from generic alternatives also limit revenue growth for branded products.

Technology and Segment Insights

By drug class, the market is segmented into first generation antipsychotics and second generation antipsychotics. Second generation drugs account for a larger share due to improved safety profiles and broader therapeutic applications. By formulation, oral tablets dominate usage, while long acting injectables are gaining traction because they enhance adherence and reduce relapse rates. By indication, schizophrenia represents the largest segment, followed by bipolar disorder and major depressive disorder with psychotic features. End users include hospitals, psychiatric clinics, and retail pharmacies, with hospitals holding a significant share due to higher patient volumes and complex case management. Regionally, North America leads the market supported by advanced healthcare systems and strong diagnosis rates. Europe follows with structured mental health programs, while Asia Pacific shows the fastest growth due to expanding healthcare access and rising awareness of psychiatric care.

Competitive and Strategic Outlook

The competitive landscape consists of multinational pharmaceutical companies and regional generic manufacturers. Strategic focus areas include product lifecycle management, formulation improvements, and expansion into emerging markets. Companies emphasize research into therapies with fewer side effects and better patient tolerability. Partnerships with healthcare providers and mental health institutions strengthen distribution networks. Portfolio diversification and cost optimization remain key strategies to address pricing pressures from generics. Regulatory compliance and clinical evidence generation shape long term competitive positioning.

The antipsychotic drugs market is positioned for steady growth through 2031. Demand will be driven by rising mental health awareness and improved treatment access. Market performance will depend on innovation, patient safety, and affordability across

regions.

Key Benefits of this Report

Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.

Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.

Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.

Actionable Recommendations: Support strategic decisions to unlock new revenue streams.

Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base Year 2025, Forecast Years 2026-2031

Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis

Competitive positioning, strategies, and market share evaluation

Revenue growth and forecast assessment across segments and regions

Company profiling including strategies, products, financials, and key

developments

Contents

1. INTRODUCTION

- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base, and Forecast Years Timeline
- 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

- 2.1. Research Design
- 2.2. Research Process

3. EXECUTIVE SUMMARY

- 3.1. Key Findings
- 3.2. Analyst View

4. MARKET DYNAMICS

- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. Threat of New Entrants
 - 4.3.4. Threat of Substitutes
 - 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 4.5. Analyst View

5. ANTI-PSYCHOTIC DRUGS MARKET BY THERAPEUTIC CLASS

- 5.1. Introduction

- 5.2. First-generation
 - 5.2.1. Market opportunities and trends
 - 5.2.2. Growth prospects
 - 5.2.3. Geographic lucrativeness
- 5.3. Second-generation
 - 5.3.1. Market opportunities and trends
 - 5.3.2. Growth prospects
 - 5.3.3. Geographic lucrativeness

6. ANTI-PSYCHOTIC DRUGS MARKET BY DISTRIBUTION CHANNEL

- 6.1. Introduction
- 6.2. Hospital Pharmacies
 - 6.2.1. Market opportunities and trends
 - 6.2.2. Growth prospects
 - 6.2.3. Geographic lucrativeness
- 6.3. Retail Pharmacies
 - 6.3.1. Market opportunities and trends
 - 6.3.2. Growth prospects
 - 6.3.3. Geographic lucrativeness
- 6.4. Online Pharmacies
 - 6.4.1. Market opportunities and trends
 - 6.4.2. Growth prospects
 - 6.4.3. Geographic lucrativeness

7. ANTI-PSYCHOTIC DRUGS MARKET BY APPLICATION

- 7.1. Introduction
- 7.2. Schizophrenia
 - 7.2.1. Market opportunities and trends
 - 7.2.2. Growth prospects
 - 7.2.3. Geographic lucrativeness
- 7.3. Dementia
 - 7.3.1. Market opportunities and trends
 - 7.3.2. Growth prospects
 - 7.3.3. Geographic lucrativeness
- 7.4. Bipolar Disorder
 - 7.4.1. Market opportunities and trends
 - 7.4.2. Growth prospects

- 7.4.3. Geographic lucrativeness
- 7.5. Depression
 - 7.5.1. Market opportunities and trends
 - 7.5.2. Growth prospects
 - 7.5.3. Geographic lucrativeness
- 7.6. Others
 - 7.6.1. Market opportunities and trends
 - 7.6.2. Growth prospects
 - 7.6.3. Geographic lucrativeness

8. ANTI-PSYCHOTIC DRUGS MARKET BY GEOGRAPHY

- 8.1. Introduction
- 8.2. North America
 - 8.2.1. By Therapeutic Class
 - 8.2.2. By Distribution Channel
 - 8.2.3. By Application
 - 8.2.4. By Country
 - 8.2.4.1. United States
 - 8.2.4.1.1. Market Trends and Opportunities
 - 8.2.4.1.2. Growth Prospects
 - 8.2.4.2. Canada
 - 8.2.4.2.1. Market Trends and Opportunities
 - 8.2.4.2.2. Growth Prospects
 - 8.2.4.3. Mexico
 - 8.2.4.3.1. Market Trends and Opportunities
 - 8.2.4.3.2. Growth Prospects
- 8.3. South America
 - 8.3.1. By Therapeutic Class
 - 8.3.2. By Distribution Channel
 - 8.3.3. By Application
 - 8.3.4. By Country
 - 8.3.4.1. Brazil
 - 8.3.4.1.1. Market Trends and Opportunities
 - 8.3.4.1.2. Growth Prospects
 - 8.3.4.2. Argentina
 - 8.3.4.2.1. Market Trends and Opportunities
 - 8.3.4.2.2. Growth Prospects
 - 8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Therapeutic Class

8.4.2. By Distribution Channel

8.4.3. By Application

8.4.4. By Country

8.4.4.1. UK

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Spain

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Others

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Therapeutic Class

8.5.2. By Distribution Channel

8.5.3. By Application

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Israel

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.5.4.4. Others

8.5.4.4.1. Market Trends and Opportunities

8.5.4.4.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Therapeutic Class

8.6.2. By Distribution Channel

8.6.3. By Application

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Indonesia

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Others

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisition, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. AstraZeneca Plc.

10.2. Pfizer, Inc

10.3. Alkermes Plc.

- 10.4. Eli Lilly and Company
- 10.5. Bristol-Myers Squibb Company
- 10.6. Johnson and Johnson
- 10.7. Teva Pharmaceutical Industries Ltd.
- 10.8. Otsuka Holdings Co. Ltd.
- 10.9. AbbVie, Inc.

I would like to order

Product name: Antipsychotic Drugs Market - Strategic Insights and Forecasts (2026-2031)

Product link: <https://marketpublishers.com/r/A11D12E57D11EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A11D12E57D11EN.html>